Symptoms, laboratory findings and treatments for COVID-19
| All patients (n=110) | Admitted (n=35) | Died (n=18) | ||||
| Median time between last ICI and COVID-19 diagnosis, days (range) | 26 (0–363) | 36 (0–363) | 17 (0–319) | |||
| Symptomatic at COVID-19 diagnosis | ||||||
| Yes* | 67/108 | (62%) | 29/35 | (83%) | 15/18 | (82%) |
| Fever | 45/67 | (67%) | 20/29 | (69%) | 8/15 | (53%) |
| Cough | 39/67 | (58%) | 15/29 | (52%) | 8/15 | (53%) |
| Dyspnea | 22/67 | (33%) | 15/29 | (52%) | 9/15 | (60%) |
| ECOG at COVID-19 diagnosis | ||||||
| 0–1 | 99 | (90%) | 25 | (72%) | 13 | (72%) |
| 2–4 | 11 | (10%) | 10 | (28%) | 5 | (28%) |
| Laboratory tests† | ||||||
| WBC ≥10,000/mm3 | 13/79 | (16%) | 10/29 | (34%) | 3/15 | (20%) |
| Lymphocytes <1500/mm3 | 36/77 | (47%) | 19/28 | (68%) | 11/14 | (79%) |
| CRP ≥100 mg/L | 11/36 | (31%) | 11/26 | (42%) | 8/14 | (57%) |
| Creatinine ≥133 µM | 10/78 | (13%) | 6/28 | (21%) | 3/14 | (21%) |
| Prednisone ≥10 mg equivalent | 15/110 | (14%) | 10/35 | (28%) | 4/18 | (22%) |
| Admission to hospital | 35/110 | (32%) | -– | -– | 16/18 | (89%) |
| Admission to intensive care unit | 7/110 | (6%) | 7/35 | (20%) | 4/18 | (22%) |
| Oxygen therapy | 22/108 | (20%) | 20/33 | (61%) | 12/16 | (75%) |
| Mechanical ventilation | 3/108 | (3%) | 3/33 | (9%) | 2/16 | (13%) |
| Use of antibiotics | 28/108 | (26%) | 24/33 | (73%) | 13/16 | (81%) |
| Use of antivirals | 7/107 | (7%) | 5/32 | (16%) | 5/16 | (31%) |
| Use of glucocorticoids | 10/107 | (9%) | 10/32 | (31%) | 3/16 | (19%) |
| Use of anti-IL6 agents | 2/108 | (2%) | 2/33 | (6%) | 2/16 | (13%) |
| Use of intravenous immunoglobulins | 1/108 | (1%) | 1/33 | (3%) | 0/16 | (0%) |
| Use of vasopressor support | 2/108 | (2%) | 2/33 | (6%) | 2/16 | (13%) |
| Use of renal replacement therapy | 1/108 | (1%) | 1/33 | (3%) | 0/16 | (0%) |
| ICI interrupted for COVID-19‡ | ||||||
| Yes | 76/104 (73%) | 24/32 (75%) | 13/17 (77%) | |||
| No | 28/104 (27%) | 8/32 (25%) | 4/17 (23%) | |||
| ICI resumed§ | ||||||
| Yes | 43/76 (57%) | 4/24 (17%) | 2/13 (15%) | |||
| No | 33/76 (43%) | 20/24 (83%) | 11/13 (85%) | |||
*Not known for 2 patients.
†Within 3 days of COVID-19 diagnosis.
‡Information on reason for interrupting ICI was not known for 6 patients.
§Number of patients who resumed ICI after discontinuing because of COVID-19.
CRP, C reactive protein; ECOG, Eastern Cooperative Oncology Group; ICI, immune checkpoint inhibition; WBC, white blood cells.